For the Inventor, By the Inventor

Enter assignee name

Bresso (MI), Italy

Newron Pharmaceuticals S.p.a.

USPTO Granted Patents = 40

CIPO Patents = 70

EPO Patents = 17

Trademarks = 2

Forward Citations = 59

Loading Chart...

Loading Chart...

77 inventors (with patents filed for the assignee):

Patricia Salvati (27 out of 47 patents)

Alessandra Restivo (13 out of 13 patents)

Piero Melloni (11 out of 47 patents)

4. Emanuela Izzo (11 out of 11 patents)

5. Cibele Sabido-David (11 out of 11 patents)

6. Florian Thaler (10 out of 15 patents)

7. Elena Colombo (9 out of 9 patents)

8. Luca Benatti (9 out of 12 patents)

9. Simona Francisconi (8 out of 8 patents)

10. Elena Barbanti (8 out of 9 patents)

11. Ruggero Fariello (7 out of 9 patents)

12. Laura Faravelli (7 out of 7 patents)

13. Carla Caccia (7 out of 16 patents)

14. Cibele Maria Sabido David (5 out of 5 patents)

15. Paolo Pevarello (4 out of 48 patents)

40 patents: Sort by Forward Citations

1. 12291495 - Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives (2025-05-06),

2. 12134589 - Process for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives (2024-11-05),

3. 9856207 - Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects (2018-01-02),

4. 9603832 - Substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2017-03-28),

5. 9585869 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2017-03-07),

6. 9505708 - Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects (2016-11-29),

7. 9492410 - Methods for treatment of Parkinson's disease (2016-11-15),

8. 9474739 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2016-10-25),

9. 9474738 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2016-10-25),

10. 9474737 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2016-10-25),

11. 9447029 - Fluorinated arylalkylaminocarboxamide derivatives (2016-09-20),

12. 9248116 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2016-02-02),

13. 9051240 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators (2015-06-09),

14. 8901176 - Methods for treatment of Parkinson's disease (2014-12-02),

15. 8846763 - High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof (2014-09-30),

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company specializing in the development of novel therapies for patients with diseases of the central and peripheral nervous system. With a focus on rare diseases, Newron seeks to improve the lives of patients by creating innovative treatments and solutions. They are dedicated to advancing the field of neuroscience and delivering transformative therapies to those in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

40 Patents

#1 in Bresso (MI)

#222 in Italy

#16,532 in the World

Bresso (MI), Italy

Newron Pharmaceuticals S.p.a.

Forward Citations = 59

77 inventors:

Patricia Salvati (27 out of 47 patents)

Alessandra Restivo (13 out of 13 patents)

Piero Melloni (11 out of 47 patents)

4. Emanuela Izzo (11 out of 11 patents)

5. Cibele Sabido-David (11 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…